OUR THERAPEUTIC AREAS
To discover new treatments that improve patients’ lives, Servier invests an average of 20% of its sales revenue (excl. generic medicines) in R&D. The Company focuses its research and development efforts in therapeutic areas where needs are substantial.
CARDIOVASCULAR
DISEASES
Cardiovascular disease and its complications are the leading cause of death worldwide [2]. We have been helping patients fight chronic diseases, including cardiovascular and metabolic diseases, for 70 years.
In these areas, Servier has built a strong reputation with a significant portfolio of medicines, and we continue to invest in the field through incremental innovation. For example, in the lifecycle management of our medicines, we develop single-tablet combinations (SPCs) to improve therapeutic adherence [3].
We recognize that adherence to treatments is critical to improving patient health and well-being, as non-adherence can severely compromise clinical outcomes [4]. Our vision is to continue advancing the field of cardiovascular innovation, helping to prevent and control cardiovascular diseases in the long term.
Our therapeutic options provide solutions for all stages of cardiovascular health, from hypertension, dyslipidemia to heart failure and angina.
To learn more about understanding your condition and enhancing your quality of life, please visit the website:
https://www.partneruzdravlju.rs/.
REFERENCES:
- *IQVIA, Analytics Link / World 76 countries – MAT Q1-2024
- Di Cesare, M., et al. The Heart of the World. Glob Heart, 2024
- Weisser, B., et al. Single Pill Regimen Leads to Better Adherence and Clinical Outcome in Daily Practice in Patients Suffering from Hypertension and/or Dyslipidemia: Results of a Meta-Analysis. High Blood Press Cardiovasc Prev, 2020
- World Health Organization. Adherence to long-term therapies: evidence for action. World Health Organization, 2003
Did you know that…
Chronic venous disease (CVD), which affects the veins, could be linked to cardiovascular disorders. People with CVD are likely to be at higher risk for other diseases, such aterosclerosis (which affects the arteries) or thromb (clots). This could be due to common risk factors such as obesity, diabetes, and smoking, and inflammation in the circulatory system.
Our company works to respond to therapeutic needs that guarantee effective protection of the vascular system, specially designed to improve the quality of life of chronic patients.
REFERENCE:
Gianesini S, et al. Cardiovascular Insights for the Appropriate Management of Chronic Venous Disease: A Narrative Review of Implications for the Use of Venoactive Drugs. Adv Ther. 2023; 40(12):5137-5154.
VENOUS AND HEMORRHOIDAL DISEASES
Both venous insufficiency and hemorrhoidal disease are chronic and progressive pathologies of the vein, impacting quality of life [3,4]. That is why it is important to treat from the onset of symptoms before they get worse and from the origin of the disease.
Venous insufficiency is a disease in which the veins in the legs have difficulty returning blood to the heart. This pathology affects the valves of the veins whose main function is to prevent venous reflux. When these valves fail, venous flow slows down, causing an abnormal accumulation of blood in the veins in the legs [5]. As a result, symptoms such as leg pain, heaviness, swelling, and varicose veins may appear.
Hemorrhoids are a network of arterial and venous vessels naturally present in the anal canal. When these venous vessels are inflamed and irritated, this is what is called hemorrhoidal disease [6]. They are the result of increased pressure in the blood vessels in the anal area and can develop inside the rectum (internal hemorrhoids) or under the skin around the anus (external hemorrhoids), which can lead to anal discomfort, itching, pain, and, in some cases, bleeding [7].
To learn more about venous insufficiency, its prevention and treatments, discover the dedicated page: https://www.detralex.rs/
REFERENCES:
- Rabe, E. et al., Epidemiology of chronic venous disorders in geographically diverse populations: results 22 from the Vein Consult Program. Int Angiol. 2012
- Riss, S., et al., The prevalence of hemorrhoids in adults. Int J Colorectal Dis. 2012
- Smith, J., et al. Chronic venous insufficiency: A comprehensive review on its underdiagnosis and impact on quality of life. Journal of Wound Care, 2022
- Doe, J., et al. Hemorrhoidal disease: A narrative review on its chronic and progressive nature and impact on quality of life. Updates in Surgery, 2024
- Harvard Health. (2021). What is venous insufficiency? Retrieved on Dec 2024 from https://www.health.harvard.edu/heart-health/what-is-venous-insufficiency
- Alonso-Coello P, et al. Clinical practice guidelines on the management of hemorrhoids and anal fissure (2007 update). Gastroenterology and hepatology. 2018; 31(10), 668–681. Available at: https://doi.org/10.1016/s0210- 5705(08)75815-1. Accessed December 2024.
- Lohsiriwat V. Hemorrhoids: from basic pathophysiology to clinical management. World Journal of Gastroenterology 2012; 18(17):2009-2017
DIABETES
The number of people with diabetes is expected to rise to 783 million by 2045 [1]. Aware that diabetes is the world’s 7th leading cause of death, but also the cause of major health complications, in addition to our vibrant in-house research, we are working in partnership with biotech companies and world-class academic groups to explore novel modes of action.
We also take part in the Innovative Medicines Initiative (IMI), a partnership between the European Commission and the European pharmaceutical industry. In particular, we are involved in three programs to foster innovation—DIRECT, IMIDIA, and RHAPSODY—and better understand why diabetes manifests more progressively in some patients than in others.
Ultimately, these programs will help identify the origin and location of the disease, as well as design adapted and personalized therapeutic strategies for homogenous patient groups.
To learn more about understanding your condition and enhancing your quality of life, please visit the website: https://www.partneruzdravlju.rs/.
REFERENCE:
1.Hong Sun et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045, Diabetes Research and Clinical Practice, Volume 183, 2022, 109119, https://doi.org/10.1016/j.diabres.2021.109119.
ONCOLOGY
Cancer is the second leading cause of death globally and, in our commitment to the development of new therapies for cancer treatment, we invest more than 70% of our R+D budget in oncology. To address patient needs through innovations in difficult-to-treat cancers, we focus on solid and onco-hematologic tumors.
Servier’s commitment in the field of oncology focuses on patients with few therapeutic options, especially those with rare cancers caused by genetic mutations. Since 2015, we have prioritized oncology, developing treatments for advanced cancers such as colorectal and pancreatic cancer, to help control the disease and give patients more time. We have also made a key drug for acute lymphoblastic leukaemia available to paediatric and adult patients. The company is focused on developing targeted therapies for glioma and bile duct cancer, based on personalized precision medicine and having a higher response rate.
We foster global collaboration between our research centers, such as the one in Boston and Symphogen, in Denmark, to drive innovation together with laboratories, biotechnology and universities. Through approximately 40 investigational partnerships, we are determined to accelerate the development of innovative treatments, improving patients’ quality of life and contributing to a healthier future.